Dr. Min Zhang is a Research Assistant Professor in the Department of Pharmaceutical Sciences and a member of the Center for Pharmacogenetics, University of Pittsburgh School of Pharmacy. She received her Ph.D. in bioinformatics from Harbin Medical University in 2009. She first went to the National Center for Toxicological Research of FDA for her postdoctoral training in computational toxicology. She later joined MD Anderson Cancer Center to continue her postdoctoral training in cancer immunotherapy and precision medicine. In 2017, Dr. Zhang joined the University of Pittsburgh as a Research Assistant Professor.
1. Wang J, Zhang Z, Guan J, Tung H, Xie J, Huang H, Chen Y, Xu M, Ren S, Li S, Zhang M, Yang D, Xie W. "Hepatocyte estrogen sulfotransferase inhibition protects female mice from concanavalin A-induced T cell-mediated hepatitis independent of estrogens". J Biol Chem. 2023 Mar;299(3):103026. doi: 10.1016/j.jbc.2023.103026. Epub 2023 Feb 15.
2. Wang Y, Zhao Y, Guo W, Yadav G, Bhaskarla C, Wang Z, Wang X, Li S, Wang Y, Chen Y, Pattarayan D, Xie W, Li S, Lu B, Kammula U, Zhang M#, Yang D#. "Genome-wide gain-of-function screening characterized lncRNA regulators for tumor 1immune response."Sci Adv. 2022 Dec 9;8(49):eadd0005. doi: 10.1126/sciadv.add0005. Epub 2022 Dec 7. (#: Co-Corresponding author)
3. Zhao Y, Wang Y, Yang D, Suh K, Zhang M#. "A computational framework to characterize the cancer drug induced effect on aging using transcriptomic data." Front Pharmacol. 2022 Jun 29;13:906429. doi: 10.3389/fphar.2022.906429. eCollection 2022.
4. Zhao Y, Zhang M, Yang D. "Bioinformatics approaches to analyzing CRISPR screen data: from dropout screens to single-cell CRISPR screens." Quantitative Biology. 2022 Dec;10(4):307-320.
5. Xie Y, Sun R, Gao L, Guan J, Wang J, Bell A, Zhu J, Zhang M, Xu M, Lu P, Cai X, Ren S, Xu P, Monga SP, Ma X, Yang D, Liu Y, Lu B, Xie W. "Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma." Hepatol Commun. 2022 May;6(5):1123-1139. doi: 10.1002/hep4.1880.
6. Zhang M, Yang D, Gold B. "Origins of nonsense mutations in human tumor suppressor genes." Mutat Res. 2021 Jul-Dec;823:111761. doi: 10.1016/j.mrfmmm.2021.111761.
7. Wan Z, Sun R, Liu YW, Li S, Sun J, Li J, Zhu J, Moharil P, Zhang B, Ren P, Ren G, Zhang M, Ma X, Dai S, Yang D, Lu B, Li S. "Targeting metabotropic glutamate receptor 4 for cancer immunotherapy." Sci Adv. 2021 Dec 10;7(50):eabj4226. doi: 10.1126/sciadv.abj4226.
8. Xi Y, Li Y, Xu P, Li S, Liu Z, Tung H, Cai X, Wang J, Huang H, Wang M, Xu M, Ren S, Li S, Zhang M, Lee Y, Huang L, Yang D, He J, Huang Z, Xie W. "The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1." Sci Adv. 2021 Sep 3;7(36):eabg9241. doi: 10.1126/sciadv.abg9241.
9. Xu P, Xi Y, Zhu J, Zhang M, Luka Z, Stolz DB, Cai X, Xie Y, Xu M, Ren S, Huang Z, Yang D, York JD, Ma X, Xie W. "Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis." Gastroenterology. 2021 Jul;161(1):271-286.e11. doi: 10.1053/j.gastro.2021.03.048.
10. Guo W, Wang Y, Yang M, Wang Z, Wang Y, Chaurasia S, Wu Z, Zhang M, Yadav GS, Rathod S, Concha-Benavente F, Fernandez C, Li S, Xie W, Ferris RL, Kammula US, Lu B, Yang D. "LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance." Sci Adv. 2021 Feb 10;7(7):eabb3555. doi: 10.1126/sciadv.abb3555.
11. Wang Y, Zhang M, Wang Z, Guo W, Yang D. "MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer." Mol Carcinog. 2020 Oct;59(10):1188-1198. doi: 10.1002/mc.23248.
12. Xiong X, Rao G, Roy RV, Zhang Y, Means N, Dey A, Tsaliki M, Saha S, Bhattacharyya S, Dhar Dwivedi SK, Rao CV, McCormick DJ, Dhanasekaran D, Ding K, Gillies E, Zhang M, Yang D, Bhattacharya R, Mukherjee P. "Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer." FASEB J. 2020 Sep;34(9):12024-12039. doi: 10.1096/fj.201902826RR.
13. Dwivedi SKD, Rao G, Dey A, Buechel M, Zhang Y, Zhang M, Yang D, Mukherjee P, Bhattacharya R. "Targeting the TGFβ pathway in uterine carcinosarcoma." Cell Stress. 2020 Aug 25;4(11):252-260. doi: 10.15698/cst2020.11.234.
14. Gao L, Li B, Wang J, Shen D, Yang M, Sun R, Tung HC, Xu M, Ren S, Zhang M, Yang D, Lu B, Wang H, Liu Y, Xie W. "Activation of Liver X Receptor α Sensitizes Mice to T-Cell Mediated Hepatitis." Hepatol Commun. 2020 Aug 12;4(11):1664-1679. doi: 10.1002/hep4.1584.
15. Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. "IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma." Cancer Letters. 2020 May 01; 477: 19-30. doi: 10.1016/j.canlet.2020.02.036.
16. Wu Z, Li S, Tang X, Wang Y, Guo W, Cao G, Chen K, Zhang M#, Guan M#, Yang D#. "Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer." Theranostics. 2020;10(9):3939-3951. doi: 10.7150/thno.39341. (#: Co-Corresponding author)
17. Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. "Data analysis of PD-1 antibody in the treatment of melanoma patients." Data in Brief. 2020 June; doi: 10.1016/j.dib.2020.105523.
18. Zhang M, Yang D, Gold B. "Origin of mutations in genes associated with human glioblastoma multiform cancer: random polymerase errors versus deamination." Heliyon. 2019 Mar 7;5(3):e01265. doi: 10.1016/j.heliyon.2019.e01265.
19. Wang Y, Wang Z, Xu J, Li J, Li S, Zhang M#, Yang D#. "Systematic Identification of Non-coding Pharmacogenomic Landscape in Cancer". Nature Communications. 2018 Aug 9; 9(1):3192. doi: 10.1038/s41467-018-05495-9. (#: Co-Corresponding author)
20. Chakraborty PK, Murphy B, Mustafi SB, Dey A, Xiong 11X, Rao G, Naz S, Zhang M, et al. "Cystathionine β-synthase regulates mitochondrial morphogenesis in ovarian cancer". FASEB Journal. 2018 Aug;32(8):4145-4157. doi: 10.1096/fj.201701095R.
21. McKenzie JA, Mbofung RM, Malu S, Zhang M, et al. "The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy". JNCI: Journal of the National Cancer Institute. 2018 Jul 1;110(7):777-786. doi: 10.1093/jnci/djx257.
22. Zhang M, Yang D, Gold B. "The Adenomatous Polyposis Coli (APC) mutation spectra in different anatomical regions of the large intestine in colorectal cancer". Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2018 May 1; 810:1-5. doi: 10.1016/j.mrfmmm.2018.04.003.
23. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; Cancer Genome Atlas Research Network, Xie W, Yang D. "€œlncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer". Cancer Cell. 2018 Apr 9;33(4):706-720.e9. doi: 10.1016/j.ccell.2018.03.006.33.
24. Mbofung RM, McKenzie JA, Malu S, Zhang M, et al. "HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes". Nature Communications. 2017 Sep 6;8(1):451. doi: 10.1038/s41467-017-00449-z.
25. Yang D, Zhang M, Gold B. "Origin of Somatic Mutations in β-Catenin versus Adenomatous Polyposis Coli in Colon Cancer: Random Mutagenesis in Animal Models versus Nonrandom Mutagenesis in Humans". Chemical Research in Toxicology. 2017 Jul 17;30(7):1369-1375. doi: 10.1021/acs.chemrestox.7b00092.
26. Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, et al. "Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia". Oncotarget. 2017 Jul 6;8(48):83354-83369. doi: 10.18632/oncotarget.19042.
27. Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, et al. "œMICU1 drives glycolysis and chemoresistance in ovarian cancer". Nature Communications. 2017 May 22;8:14634. doi: 10.1038/ncomms146"34.
28. Zhang M, Liu G, Xue F, et al. "Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer". Gynecologic Oncology. 2016 April, 141(1): 57'“64. doi: 10.1016/j.ygyno.2016.01.004.
29. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, et al. "Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition". Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9.
30. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature communications. 2016, Apr 4;7:11169. doi: 10.1038/ncomms11169.
31. Westin J, Chu F, Zhang M, et al. "Safety and Activity of Programmed Death-1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Phase II Trial". The Lancet Oncology. 2014, 15(1): 69-77.
32. Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, et al. "Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance". Blood. 2014, 123(17): 2691-702.
33. Rawal S, Chu F, Zhang M, et al. "Cross talk between follicular helper T cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment". The Journal of Immunology. 2013, 190(12): 6681-6693.
34. Kojima K, Kornblau S, Ruvolo Vivian, Dilip A, Duvvuri S, Davis, R, Zhang M, et al."Prognostic impact and targeting of CRM1 in acute myeloid leukemia". Blood. 2013, 121(20): 4166-4174.
35. Zhang M, Chen M, Tong W. "Is Toxicogenomics a More Reliable and Sensitive Biomarker than Conventional Indicators from Rats To Predict Drug-Induced Liver Injury in Humans". Chemical Research in Toxicology. 2012, 25(1): 122-129.
36. Chen M, Zhang M, Borlak J, Tong W. "A Decade of Toxicogenomic Research and Its Contribution to Toxicological Scienceâ". Toxicological Sciences. 2012, 130(2): 217-228.
37. Ding Y, Chen M, Liu Z, Ding D, Ye Y, Zhang M, et al. "atBioNet" “an Integrated Network Analysis Tool for Genomics and Biomarker Discovery". BMC Genomics. 2012, DOI: 10.1186/1471-2164-13-325.
38. Khalili J, Liu S, Rodriguez-Cruz T, Whittington M, Wardell S, Liu C, Zhang M, Cooper Z, Frederick D, Li Y, Zhang M, et al. "Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression via Induction of Interleukin-1 in Melanoma". Clinical Cancer Research. 2012,18(19): 5329-5340.
39. Yao C*, Zhang M*, Zou JF, et al. "Functional modules with disease discrimination abilities for various cancers". Science China-Life Sciences. 2011, 54(2): 189-193 (* equal contribution).
40. MAQC Consortium (including Zhang M). "The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models". Nature Biotechnology. 2010, 28(8): 827-838.
41. Gu Y, Yang D, Zou J, Ma W, Wu R, Zhao W, Zhang Y, Xiao H, Gong X, Zhang M, et al. "Systematic interpretation of comutated genes in large-scale mutation profile". Molecular Cancer Therapeutics. 2010, 9(8): 2186-2195.
42. Zhu J, Xiao H, Shen X, Wang J, Zou J, Zhang L, Yang D, Ma W, Yao C, Gong X, Zhang M, et al. "Viewing cancer genes from co-evolving gene modules". Bioinformatics. 2010, 26(7): 919-924.
43. Zhang M, Zhang L, Zou J, et al. "Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes". Bioinformatics. 2009, 25(13): 1662-1668.
44. Wang D, Wang C, Zhang L, Xiao H, Shen X, Ren L, Zhao W, Hong G, Zhang Y, Zhu J, Zhang M, et al. â"Evaluation of cDNA Microarray Data by Multiple Clones Mapping to the Same Transcript". OMICS: A Journal of Integrative Biology. 2009, 13(6): 493-499.
45. Zhang M, Yao C, Guo Z, et al. "Apparently low reproducibility of true differential expression discoveries in microarray studies". Bioinformatics. 2008, 24(18): 2057-2063.
46. Li Y, Guo Z, Peng C, Liu Q, Ma W, Wang J, Yao C, Zhang M, et al. "Identifying cancer genes from cancer mutation profiles by cancer functions". Science China-Life Sciences. 2008, 51(6): 569-574.
47. Yang D, Li Y, Xiao H, Guo Z, Liu Q, Zhang M, et al. "Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories". Bioinformatics. 2008, 24(2): 265-271.
48. Yang D, Li Q, Hao X, Li C, Lv Y, Wang D, Zhong G, Zhang M, et al. "Studying molecular mechanisms of depression by a rat model based on gene expression profiles and gene functional modules". Chinese High Technology Letters. 2007, 17(5).
49. Guo Z, Li Y, Ma W, Yang D, Wang D, Zhang M, et al."Finding finer functions for partially characterized proteins by protein-protein interaction networks". Chinese Science Bulletin. 2007, 52(24): 3363-3370.
50. Guo Z, Li Y, Gong X, Yao C, Ma W, Wang D, Li Y, Zhu J, Zhang M, et al. "Edge-based scoring and searching method for identifying condition-responsive protein-protein interaction subnetwork". Bioinformatics. 2007, 23(16): 2121-2128.
51. Zhu J, Wang J, Guo Z, Zhang M, et al. "GO-2D: identifying 2-dimensional cellularlocalized functional modules in Gene Ontology". BMC Genomics. 2007, 8:30 DOI: 10.1186/1471-2164-8-30.
52. Zhu J, Guo Z, Zhang M, et al. "Interaction of cellular-localized signature modules in response to prostate cancer". Progress In Natural Science. 2007, 17(11).
53. Xu J, Guo Z, Zhang M, et al. "Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules". Molecular Medicine. 2006, 12(1-3): 25-33.
54. Zhang M, Zhu J, Guo Z, et al."Identifying disease feature genes based on cellular localized gene functional modules and regulation networks". Chinese Science Bulletin. 2006, 51(15): 1848-1856.
